



COVID-19: Hydroxychloroquine and the TRUTH

Paul Marik MD, FCCM, FCCP

HCQ for COVID-19

420 studies from **8,657** scientists
591,536 patients in **59** countries


Significantly lower risk for **mortality, hospitalization, progression, recovery, cases, and viral clearance.**

66%, 22% lower risk for early and late treatment CI 54-74%, 18-26%; 38, 271 studies

34% lower risk in **10 early treatment RCTs** CI -1-56%


76% lower **mortality** in **17** early treatment studies CI 61-85%

COVID-19 HYDROXYCHLOROQUINE STUDIES. FEB 2025. C19HCQ.ORG



Time when COVID-19 studies showed efficacy

c19early.org
February 2025



Timeline for when studies showed efficacy - [details and limitations](#). 0.5% of treatments show efficacy.

COST PER LIFE SAVED FROM NNT IN STUDIES TO DATE

Melatonin	\$8 ⁹ _{48%}	Vitamin A	\$45 ⁵ _{30%}	Budesonide	\$574 ¹² _{26%}	Bebtelovimab	\$737,601 ⁴ _{60%}
Vitamin D	\$10 ⁷² _{38%}	Curcumin	\$59 ⁸ _{63%}	Azvudine	\$1,248 ²³ _{30%}	Remdesivir	\$1,558,440 ⁶⁶ _{1%}
Alkalinization	\$11 ⁸ _{46%}	Famotidine	\$94 ²¹ _{18%}	Favipiravir	\$1,935 ⁴⁰ _{11%}	Molnupiravir	\$2,400,867 ²⁷ _{13%}
Zinc	\$15 ²¹ _{30%}	Metformin	\$121 ⁷¹ _{37%}	Tixagev../c..	\$74,506 ¹⁰ _{42%}	Conv. Plasma	N/A ⁸² _{-2%}
Vitamin C	\$18 ⁴⁵ _{19%}	Quercetin	\$127 ⁵ _{61%}	Regdanvimab	\$139,860 ⁷ _{63%}	Acetaminophen	N/A ¹⁴ _{-24%}
HCQ	\$26 ²⁵² _{27%}	Probiotics	\$172 ¹⁰ _{59%}	Sotrovimab	\$299,464 ¹⁴ _{46%}	PPIs	N/A ²⁰ _{-40%}
Colchicine	\$26 ⁴³ _{28%}	Antiandrogens	\$179 ³² _{37%}	Bamlaniv../e..	\$301,549 ¹³ _{54%}	Brensocatib	N/A ¹ _{-41%}
Ivermectin	\$26 ⁵³ _{47%}	Nigella Sativa	\$187 ⁵ _{57%}	Casirivimab/..	\$452,469 ¹¹ _{20%}		
Aspirin	\$41 ⁶⁷ _{9%}	Fluvoxamine	\$411 ¹⁰ _{44%}	Paxlovid	\$543,982 ³⁹ _{25%}		

February 2025
c19early.org